ClinicalTrials.gg
Active, not recruitingNCT07840755Updated Oct 5, 2026

Effects of Nordic Pole Walking in Adults With Forward Head Posture

An interventional study of Nordic Pole Walking and General Walking in Forward Head Posture, sponsored by Sahmyook University. Active, not recruiting at 1 site in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Sahmyook University · Not applicable, Interventional, and Treatment

Updated Oct 5, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 31 studies in Neck Pain with a site in Korea, Republic of — 3 open to participants now, 6 under way, none of them phase 3. Neck Pain · Korea, Republic of.

Planned enrollment
15th of 22
44 · median 60
Started
2026
with 1 other
No phase
20 of 31
1 open now
Registered
31st of 31
by date
Lead sponsor
3 of 31
Sahmyook University

Among the 31 studies in Neck Pain with a site in Korea, Republic of, this one is the 15th largest by planned enrollment of the 22 interventional ones, is one of 2 that started in 2026, is one of 20 with no phase, and was the 31st registered.

By phase

31 studies; the count open now beside each. This study's row is marked.

No phasethis study20 · 1 open
Observational9 · 2 open
Phase 21 · 0 open
Phase 41 · 0 open

By the year they started

First in 2009; this study’s year is marked. 2 started in 2026.

Size and results

Median enrollment 60 across the 22 interventional studies, 111 across the 9 observational. Of the 19 that completed or were terminated, 2 (11%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 31 studies in Neck Pain with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This randomized controlled trial aims to investigate the effects of Nordic pole walking on pain, neck-related disability, pulmonary function, respiratory muscle strength, and postural alignment in adults with forward head posture and neck pain.

Participants will be randomly assigned to either a Nordic pole walking group or a general walking group. Both groups will participate in a 6-week walking program, three times per week, with each session lasting 40 minutes.

Neck-related disability and pain will be assessed using the Neck Disability Index (NDI) and Visual Analog Scale (VAS). Pulmonary function will be assessed using forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and the FEV1/FVC ratio. Respiratory muscle strength will be evaluated using maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), and postural alignment will be assessed using the craniovertebral angle (CVA). Measurements will be performed before and after the 6-week intervention.

03

Conditions studied

  • Forward Head Posture

Browse trials for

Keywords

  • Nordic Pole Walking
  • Forward Head Posture
  • Neck Pain
  • Pulmonary Function
  • Respiratory Muscle Strength
  • Craniovertebral Angle
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 years or older
  • Craniovertebral angle (CVA) \< 50°
  • Neck pain lasting at least 3 months
  • Visual Analog Scale (VAS) score > 4

Exclusion criteria

Exclusion Criteria:

  • Individuals currently participating in an exercise program related to neck pain management or postural correction
  • Individuals with musculoskeletal disorders that limit the ability to perform the exercise intervention
  • Individuals with respiratory diseases such as asthma, (COPD), bronchiectasis, or pneumonia
  • Individuals who have been regular smokers within the past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Nordic Pole Walking Group

    Participants assigned to this group will perform Nordic pole walking for 6 weeks, 3 sessions per week, with each session lasting 40 minutes.

    Behavioral: Nordic Pole Walking

  • Active comparator
    General Walking Group

    Participants assigned to this group will perform general walking for 6 weeks, 3 sessions per week, with each session lasting 40 minutes.

    Behavioral: General Walking

Interventions

  • BehavioralNordic Pole Walking

    Participants will perform Nordic pole walking using Nordic walking poles for 6 weeks, 3 sessions per week, with each session lasting 40 minutes. Participants will walk with coordinated upper- and lower-extremity movements while actively planting and pushing the poles during walking.

    Also known as: Nordic Walking

  • BehavioralGeneral Walking

    Participants will perform general walking for 6 weeks, 3 sessions per week, with each session lasting 40 minutes.

06

What researchers measure

Primary outcomes

  1. Visual Analog Scale (VAS) for Neck Pain

    Neck pain intensity will be assessed using a 10-cm horizontal Visual Analog Scale (VAS). The left end of the line represents no pain (0), and the right end represents very severe pain (10). To minimize bias, numerical values will not be displayed on the line. Participants will mark the point that best represents their perceived pain intensity, and the distance from the left end to the marked point will be measured with a ruler. Higher scores indicate greater pain intensity.

    Time frame: Baseline and 6 weeks

  2. Neck Disability Index (NDI)

    Neck-related disability will be assessed using the Neck Disability Index (NDI), a 10-item self-reported questionnaire. Each item is scored from 0 to 5, resulting in a raw total score ranging from 0 to 50. The raw total score will be multiplied by 2 and converted to a 0-100 scale, with higher scores indicating greater neck-related disability. The change in NDI score from baseline to 6 weeks will be evaluated.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Forced Vital Capacity (FVC)

    Pulmonary function will be assessed using a MicroLab 3300 spirometer. Participants will be seated upright and perform forced expiratory maneuvers through a mouthpiece following maximal inspiration. FVC will be measured over three trials.

    Time frame: Baseline and 6 weeks

  2. Forced Expiratory Volume in One Second (FEV1)

    FEV1 will be measured using a MicroLab 3300 spirometer with participants seated upright. Participants will perform forced expiratory maneuvers following maximal inspiration. FEV1 will be measured three times, and the mean of the three measurements will be used for analysis.

    Time frame: Baseline and 6 weeks

  3. FEV1/FVC Ratio

    The FEV1/FVC ratio will be calculated from the measured forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) values obtained using a MicroLab 3300 spirometer. Higher values indicate a greater proportion of the vital capacity exhaled during the first second of forced expiration.

    Time frame: Baseline and 6 weeks

  4. Maximal Inspiratory Pressure (MIP)

    Respiratory muscle strength will be assessed using a MicroRPM device with participants in a seated position. Maximal inspiratory pressure (MIP) will be measured from residual volume (RV). At least three and up to eight measurements will be performed. The highest value among measurements showing variability within 10% will be used for analysis.

    Time frame: Baseline and 6 weeks

  5. Maximal Expiratory Pressure (MEP)

    Respiratory muscle strength will be assessed using a MicroRPM device with participants in a seated position. Maximal expiratory pressure (MEP) will be measured from total lung capacity (TLC). At least three and up to eight measurements will be performed. The highest value among measurements showing variability within 10% will be used for analysis.

    Time frame: Baseline and 6 weeks

  6. Craniovertebral Angle (CVA)

    Postural alignment will be assessed using the craniovertebral angle (CVA). A camera will be positioned 104 inches from the participant at a height of 33 inches. Participants will stand upright in a comfortable posture with their arms at their sides after performing three consecutive maximal cervical flexion and extension movements. The CVA will be defined as the angle between a horizontal line passing through the C7 spinous process and a line connecting the tragus of the ear to the C7 spinous process. Three photographs will be taken, and the mean CVA value will be used for analysis. Lower CVA values indicate a greater degree of forward head posture.

    Time frame: Baseline and 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2026, 1 month after the start.

Of 763 non-industry interventional studies with no phase under Neck Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's planned 1 month is below that.

Counting every sponsor, half of 772 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Sep 25, 2026
StartActual
Sep 28, 2026
Primary completionEst.
Nov 11, 2026was Oct 2026
CompletionEst.
Nov 11, 2026was Oct 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Start date
Sep 6, 2026→Sep 28, 2026 (actual)
Oct 5, 2026
Primary completion
Oct 18, 2026→Nov 11, 2026
Oct 5, 2026
Study completion
Oct 18, 2026→Nov 11, 2026
Oct 5, 2026
Registered
First appeared on the registry
Sep 25, 2026
Show all 2 updates
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    Start date Sep 6, 2026→Sep 28, 2026 (now actual)
    Primary completion Oct 18, 2026→Nov 11, 2026
    Study completion Oct 18, 2026→Nov 11, 2026
    + 3 other changes: verification date, site details and contact details
  2. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07840755
Lead sponsor
Sahmyook University
Responsible party
CHEON YEONGHUN (Principal Investigator, Sahmyook University) — Principal investigator
First posted
Sep 25, 2026
Start date
Sep 28, 2026
Primary completion
Nov 11, 2026 (estimated)
Completion
Nov 11, 2026 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion